Search Results 1581-1590 of 21900 for Inhibition
Prior or concurrent therapy with a Janus kinase inhibitor or Bruton's tyrosine kinase inhibitor. Participating Mayo Clinic locations. Study statuses change ...
... inhibitor (pembrolizumab, atezolizumab, or nivolumab). NOTE: Pathology reports documenting the diagnosis of NSCLC are required to be reviewed to confirm ...
Developing a new drug for women with resistance to aromatase inhibitors; Identifying mechanisms for why some people do not respond to endocrine treatment ...
No prior treatment with BRAF or MEK inhibitors; Steroid dosing stable for at least 4 days prior to registration. Not pregnant and not nursing; for women of ...
... inhibition of these pathways via engagement of a single kinase. Here we review the form, function and pharmacology of AMPK with special attention to its ...
Has received prior treatment with a PRMT5 inhibitor, or MAT2A inhibitor 2. Prior enrollment in any phase 3 clinical trial of RMC-6236 or RMC-9805 3. Known ...
... inhibitors in this high-risk population. Read More on PubMed. Additional contact information. Non-cancer trials contact form. Phone: 800-664-4542 (toll-free).
NFkappaB inhibition decreases hepatocyte proliferation but does not alter apoptosis in obstructive jaundice. J Surg Res. 2003 Oct; 114 (2):110-7. View PubMed ...
Prior treatment with ibrutinib or other Bruton's tyrosine kinase inhibitors or prior randomization in any other clinical study evaluating ibrutinib; The ...
... inhibitors (e.g. sitagliptin) alone or in combination with metformin. Participation eligibility. Participant eligibility includes age, gender, type and stage ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!